{
    "clinical_study": {
        "@rank": "105705", 
        "arm_group": [
            {
                "arm_group_label": "A/17/CA/2009/38 (H1N1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Stabilizer", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and reactogenicity of Pandemic Live\n      Attenuated Influenza Vaccine (PLAIV) manufactured by GPO, Thailand, and to evaluate humoral\n      immune response of the above vaccine after intranasal application by using HAI test, micro\n      neutralization assays."
        }, 
        "brief_title": "Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais", 
        "completion_date": {
            "#text": "January 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "Part A: 24 volunteers will be enrolled and divided into 2 groups -12 volunteers in each of 2\n      groups receiving either 5.0-6.5 log 10 EID50 or 6.6-7.5 log10 EID50 respectively. 9 who will\n      received vaccine vaccine strain and 3 who will received placebo.\n\n      Part B: Total 324 participants will randomized into 2 group using 3:1 ratio (300\n      vaccines:100 placebos). There are 3 stratified age groups: >12-18 years, >18-49 years and\n      >49 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy\n\n          -  Age 9 - >49 years old\n\n          -  Having Thai ID  card or equivalent\n\n          -  Are seronegative to the specific H1N1 influenza virus determined by antibody titer\n             less than 1:10 by HAI test to the corresponding antigen\n\n          -  Anti HIV - Negative\n\n          -  All hematology & biochemistry within normal range\n\n          -  Able to read and write and sign written informed consent\n\n        Exclusion Criteria:\n\n          -  Known history of egg allergy\n\n          -  Having had recently influenza infection confirmed as H1N1 (indeed all other types if\n             Influenza and vaccination with seasonal vaccine will not interfere)\n\n          -  History of bronchial asthma\n\n          -  History of chronic lung diseases\n\n          -  History of chronic rhinitis\n\n          -  History of immunodeficiency state\n\n          -  History of immunosuppression\n\n          -  Acute infectious and noninfectious diseases (within 2 weeks)\n\n          -  Exacerbation of chronic diseases or cancer or HIV positives\n\n          -  Anamnestic leukocytosis, hepatitis B and C positives\n\n          -  The volunteers who have been taking immunoglobulin products or have had a blood\n             transfusion during past three months before the beginning of the experiment\n\n          -  Participation in other research study\n\n          -  Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding\n\n          -  Any concomitant medication with Aspirin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "9 Years"
        }, 
        "enrollment": {
            "#text": "363", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 11, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666262", 
            "org_study_id": "GPO FLU VACCINE-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "A/17/CA/2009/38 (H1N1)", 
                "description": "Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)", 
                "intervention_name": "Vaccine A/17/CA/2009/38 (H1N1)", 
                "intervention_type": "Biological", 
                "other_name": "GPO Flu Vaccine-01"
            }, 
            {
                "arm_group_label": "Stabilizer", 
                "description": "5% sucrose", 
                "intervention_name": "Placebo:Stabilizer", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "FLU", 
            "H1N1", 
            "GPO", 
            "PLAIV"
        ], 
        "lastchanged_date": "August 10, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10400"
                }, 
                "name": "Faculty of Tropical Medicine, Mahidol University"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais", 
        "overall_official": {
            "affiliation": "Mahidol University", 
            "last_name": "Prof.Punnee Pitisuttithum, MBBS,DTM&HDipGrad", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Thailand: Ethical Committee", 
                "Thailand: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_outcome": {
            "measure": "Systemic reaction and local reaction (vital sign, temperature)", 
            "safety_issue": "Yes", 
            "time_frame": "11/2 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666262"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mahidol University", 
            "investigator_full_name": "Punnee Pitisuttithum", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Peak immunogenicity blood specimen and nasal washing for accessing immune response IgA.\nNasal swab on D2, D3, D5, D7 after immunization. Blood for ASC assay at D0 (baseline) and D7 after each dose of vaccine.", 
            "measure": "Humoral immune response", 
            "safety_issue": "No", 
            "time_frame": "11/2 year"
        }, 
        "source": "Mahidol University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}